News Article
BluGlass proposes to buy out SPTS EpiBlu shares
Australia's BluGlass intends to use 5 percent of its enlarged share capital to buy out the U.K.'s SPTS shares in EpiBlu. This is a joint venture between the two companies and is focused on LED growth using RPCVD
BluGlass has made a proposal (the “Capital Restructure") regarding reorganisation of capital within the company.
BluGlass is an innovator in Remote Plasma Chemical Vapour Deposition (RPCVD) which it uses in the growth of LEDs and solar cells. The company is based in Sydney, Australia.
The first proposal involves the sale of all of the shares in its LED joint venture, EpiBlu, held by SPTS Technologies UK Limited (SPTS), to BluGlass.
The second is the issue of 15,973,678 fully paid ordinary shares in the capital of BluGlass to SPTS, which equates to 5 percent of BluGlass’ enlarged share capital.
Shareholders have been asked to vote as to whether they accept the Capital Restructure.
BluGlass stresses that an independent expert has concluded that the capital restructure is fair and reasonable to shareholders not associated with SPTS.
BluGlass is an innovator in Remote Plasma Chemical Vapour Deposition (RPCVD) which it uses in the growth of LEDs and solar cells. The company is based in Sydney, Australia.
The first proposal involves the sale of all of the shares in its LED joint venture, EpiBlu, held by SPTS Technologies UK Limited (SPTS), to BluGlass.
The second is the issue of 15,973,678 fully paid ordinary shares in the capital of BluGlass to SPTS, which equates to 5 percent of BluGlass’ enlarged share capital.
Shareholders have been asked to vote as to whether they accept the Capital Restructure.
BluGlass stresses that an independent expert has concluded that the capital restructure is fair and reasonable to shareholders not associated with SPTS.
